OFFICIAL PUBLICATION OF

by its subsidiary APPco

MSD melanoma drug listed

Megan Haggan 20/04/2015

melanoma: dermatologist examines mole on woman's shoulder

A new treatment for advanced melanoma which has seen significant media attention is now available in Australia. MSD announced that its anti-PD1 immunotherapy KEYTRUDA (pembrolizumab) has been registered by the TGA for the treatment of the most deadly form of skin cancer – advanced melanoma. The treatment has been the subject of a Change.org petition

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

‘Consumer confusion, pharmacist frustration’ if current system continues

The first and foremost role of "expanded scope" is the HMR and collaborative medication management. A clear no brainer which…

Big Pharma

‘I can feel the walls closing in on me as this snowballs’

I'm yet to encounter a corporate provider, Debbie, with the benefits you describe around quality improvement with the corporate business…

Kelly Abbott

‘I can feel the walls closing in on me as this snowballs’

I would argue quality varies in any profession. Most GPs will not refer to a provider where the quality is…

Big Pharma

Wesfarmers targets affordable healthcare

When healthcare is treated as a commodity and patients regarded as consumers, health outcomes are compromised and overall healthcare spending…

Edward Hatfield

MSD melanoma drug listed

Previous Council urges Aussies to consider bowel cancer

Next TGA upgrades eBusiness website

In the beginning

The signs of ageing

Hyperpigmentation

How to avoid dry skin

MENU

Previous Council urges Aussies to consider bowel cancer

Next TGA upgrades eBusiness website

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.